Physician profile
Timothy E Byun
NPI 1871545012
$98,180.13
in general payments reported to CMS, 2019-2025
95 companies · $5,583 in 2025
The $5,583 reported for 2025 was more than what 83% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46K · 2020: $8,207 · 2021: $8,123 · 2022: $8,631 · 2023: $15K · 2024: $6,726 · 2025: $5,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Consulting Fee: $9,479 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,100 · Travel and Lodging: $1,166 · Honoraria: $360 · Education: $23.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,232.12 |
| Consulting Fee | $9,479.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,100.00 |
| Travel and Lodging | $1,165.97 |
| Honoraria | $360.00 |
| Education | $23.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $30,259.07 | 2019-2025 | Keytruda, Lynparza, Keytruda Qlex |
| E.R. Squibb & Sons, L.L.C. | $22,707.63 | 2019-2025 | Opdivo, Opdualag |
| Astrazeneca Pharmaceuticals LP | $12,274.59 | 2019-2025 | Tagrisso, Imfinzi, Calquence |
| Exelixis INC. | $5,128.36 | 2019-2025 | Cabometyx |
| Celgene Corporation | $4,767.18 | 2019-2025 | Reblozyl, Pomalyst, Opdivo |
| Eisai INC. | $1,832.20 | 2019-2025 | |
| Pfizer INC. | $1,664.70 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $1,571.68 | 2019-2025 | |
| Amgen INC. | $1,330.96 | 2019-2023 | Lumakras, Blincyto, Kyprolis |
| Janssen Scientific Affairs, LLC | $1,090.00 | 2023 | |
| Seagen INC. | $1,003.01 | 2019-2023 | Tukysa, Adcetris |
| Daiichi Sankyo INC. | $853.54 | 2019-2025 | Enhertu, Datroway, Vanflyta |
| Janssen Biotech, INC. | $839.70 | 2019-2025 | Erleada, Darzalex, Rybrevant |
| Abbvie INC. | $823.75 | 2019-2025 | Venclexta |
| Genentech USA, INC. | $778.53 | 2019-2025 | Tecentriq, Phesgo, Venclexta |
Show all 89 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $760.11 | 2019-2025 | Braftovi, Mektovi, Tukysa |
| Glaxosmithkline, LLC. | $719.91 | 2020-2025 | Ojjaara, Jemperli, Zejula |
| Pharmacyclics LLC, An Abbvie Company | $713.07 | 2019-2023 | Imbruvica, Epkinly |
| Genzyme Corporation | $517.28 | 2019-2025 | |
| Astellas Pharma US INC | $500.40 | 2019-2025 | Xtandi, Vyloy, Padcev |
| Gilead Sciences, INC. | $492.95 | 2019-2025 | Trodelvy |
| Bayer Healthcare Pharmaceuticals INC. | $477.56 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $410.76 | 2019-2025 | Fruzaqla, Alunbrig, Iclusig |
| Beigene USA, INC. | $400.37 | 2020-2024 | Brukinsa |
| Incyte Corporation | $390.68 | 2021-2025 | Jakafi, Monjuvi, Zynyz |
| Puma Biotechnology, INC. | $351.91 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $340.90 | 2020-2025 | Libtayo |
| Sumitomo Pharma America, INC. | $273.24 | 2023-2025 | Orgovyx |
| Karyopharm Therapeutics INC. | $257.71 | 2021-2025 | Xpovio |
| Foundation Medicine, INC. | $252.57 | 2019-2022 | |
| Myovant Sciences INC. | $233.17 | 2021-2022 | |
| Coherus Oncology, INC. | $217.61 | 2021-2025 | Loqtorzi, Udenyca |
| Emd Serono, INC. | $209.65 | 2019-2025 | |
| Pharmaessentia USA Corporation | $178.40 | 2024-2025 | Besremi |
| Kite Pharma, INC. | $176.51 | 2020-2023 | Yescarta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.12 | 2019-2025 | Gilotrif |
| Tersera Therapeutics LLC | $164.11 | 2019-2024 | Zoladex |
| Genmab U.S., INC. | $157.41 | 2023-2025 | Epkinly |
| Alexion Pharmaceuticals, INC. | $145.71 | 2019-2025 | Ultomiris |
| Ipsen Biopharmaceuticals, INC | $144.41 | 2019-2025 | Onivyde, Somatuline Depot |
| Beone Medicines USA, INC. | $140.00 | 2025 | Brukinsa, Tevimbra |
| Aveo Pharmaceuticals, INC. | $127.80 | 2022-2025 | |
| Stemline Therapeutics INC. | $121.04 | 2023-2025 | Orserdu, Elzonris |
| Lilly USA, LLC | $120.75 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Blueprint Medicines Corporation | $118.90 | 2022-2025 | Ayvakit |
| Geron Corporation | $112.86 | 2025 | Rytelo |
| Pharmacosmos Therapeutics INC. | $106.75 | 2024-2025 | Monoferric |
| Rigel Pharmaceuticals, INC. | $103.88 | 2021-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Acceleron Pharma, INC. | $85.94 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $84.66 | 2021-2025 | |
| Deciphera Pharmaceuticals INC. | $83.37 | 2021-2025 | Romvimza, Qinlock |
| Alnylam Pharmaceuticals INC. | $82.37 | 2021-2022 | |
| Sobi, INC | $80.43 | 2020-2025 | |
| Taiho Oncology, INC. | $76.91 | 2019-2024 | |
| Amag Pharmaceuticals, INC. | $76.57 | 2019-2021 | |
| Epizyme, INC. | $63.01 | 2020-2021 | |
| Dendreon Pharmaceuticals LLC | $62.85 | 2019-2023 | Provenge |
| Syndax Pharmaceuticals, INC. | $62.15 | 2025 | |
| Servier Pharmaceuticals LLC | $61.77 | 2021-2022 | |
| Adc Therapeutics America, INC. | $61.50 | 2023-2025 | |
| Acrotech Biopharma INC. | $57.31 | 2021-2024 | Beleodaq |
| Springworks Therapeutics, INC. | $55.96 | 2024 | Ogsiveo |
| Eusa Pharma (US) LLC | $54.32 | 2020-2021 | |
| Csl Behring | $50.05 | 2019-2025 | Idelvion, Afstyla |
| Accord Healthcare, INC. | $48.89 | 2024-2025 | |
| Morphosys, US INC. | $38.20 | 2021-2022 | |
| West Therapeutics Development, LLC | $33.40 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $32.31 | 2019 | |
| Dova Pharmaceuticals | $30.38 | 2019-2020 | |
| Tempus Ai, INC | $29.22 | 2024 | |
| Secura Bio, INC. | $24.62 | 2019-2020 | |
| Tesaro, INC. | $24.38 | 2019 | |
| Blue Earth Diagnostics | $23.95 | 2020 | |
| Genentech, INC. | $23.62 | 2023 | Lunsumio, Columvi |
| Recordati_rare_diseases_inc. | $22.93 | 2025 | Enjaymo |
| Caris Mpi, INC. | $22.92 | 2025 | Mi Cancer Seek |
| Legend Biotech USA INC. | $22.83 | 2025 | Carvykti |
| Iovance Biotherapeutics, INC. | $22.48 | 2025 | Amtagvi |
| Abbott Laboratories | $22.06 | 2019 | |
| Sirtex Medical INC | $17.47 | 2023 | Sir-Spheres Microspheres |
| Mylan Institutional INC. | $16.17 | 2019 | |
| Emmaus Medical, INC. | $16.05 | 2020 | |
| Helsinn Therapeutics (U.S.), INC. | $15.04 | 2019 | |
| Kyowa Kirin, INC. | $13.98 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $13.05 | 2019 | |
| Sanofi-Aventis U.S. LLC | $12.47 | 2020 | |
| Cti Biopharma Corp. | $11.73 | 2022 | |
| Aurobindo Pharma USA, INC. | $11.26 | 2020 | |
| Janssen Pharmaceuticals, INC | $2.15 | 2019 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Byun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.